Literature DB >> 23072837

Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.

Márcio Gerhardt Soeiro-de-Souza1, Giacomo Salvadore, Ricardo Alberto Moreno, Maria Concepción Garcia Otaduy, Kalil T Chaim, Wagner F Gattaz, Carlos A Zarate, Rodrigo Machado-Vieira.   

Abstract

B-cell lymphoma 2 (Bcl-2) is an important regulator of cellular plasticity and resilience. In bipolar disorder (BD), studies have shown a key role for a Bcl-2 gene single-nucleotide polymorphism (SNP) rs956572 in the regulation of intracellular calcium (Ca(2+)) dynamics, Bcl-2 expression/levels, and vulnerability to cellular apoptosis. At the same time, Bcl-2 decreases glutamate (Glu) toxicity in neural cells. Abnormalities in Glu function have been implicated in BD. In magnetic resonance spectroscopy (MRS) studies, anterior cingulated cortex (ACC) Glu levels have been reported to be increased in bipolar depression and mania, but no study specifically evaluated ACC Glu levels in BD-euthymia. Here, we compared ACC Glu levels in BD-euthymia compared with healthy subjects using (1)H-MRS and also evaluated the selective role of the rs956572 Bcl-2 SNP in modulating ACC Glu and Glx (sum of Glu and glutamine) in euthymic-BD. Forty euthymic subjects with BD type I and forty healthy controls aged 18-40 were evaluated. All participants were genotyped for Bcl-2 rs956572 and underwent a 3-Tesla brain magnetic resonance imaging examination including the acquisition of an in vivo PRESS single voxel (2 cm(3)) (1)H-MRS sequence to obtain metabolite levels from the ACC. Euthymic-BD subjects had higher Glu/Cre (creatine) and Glx/Cre compared with healthy controls. The Bcl-2 SNP AA genotype was associated with elevated ACC Glu/Cre and Glx/Cre ratio in the BD group but not in controls. The present study reports for the first time an increase in ACC Glu/Cre and Glx/Cre ratios in BD-euthymia. Also, Bcl-2 AA genotype, previously associated with lower Bcl-2 expression and increase intracellular Ca(2+), showed to be associated with increased ACC Glu and Glx levels in euthymic-BD subjects. The present findings reinforce a key role for glutamatergic system dysfunction in the pathophysiology of BD, potentially involving modulatory effects by Bcl-2 in the ACC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23072837      PMCID: PMC3547197          DOI: 10.1038/npp.2012.203

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  57 in total

Review 1.  Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression.

Authors:  A A Nierenberg; L M DeCecco
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

2.  A nontoxic and versatile protein salting-out method for isolation of DNA.

Authors:  J Laitinen; J Samarut; E Hölttä
Journal:  Biotechniques       Date:  1994-08       Impact factor: 1.993

Review 3.  BCL-2 family: regulators of cell death.

Authors:  D T Chao; S J Korsmeyer
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

4.  Increased cerebrospinal fluid glutamine levels in depressed patients.

Authors:  J Levine; K Panchalingam; A Rapoport; S Gershon; R J McClure; J W Pettegrew
Journal:  Biol Psychiatry       Date:  2000-04-01       Impact factor: 13.382

Review 5.  Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression.

Authors:  W C Drevets
Journal:  Prog Brain Res       Date:  2000       Impact factor: 2.453

6.  Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment.

Authors:  M C Mauri; A Ferrara; L Boscati; S Bravin; F Zamberlan; M Alecci; G Invernizzi
Journal:  Neuropsychobiology       Date:  1998       Impact factor: 2.328

7.  Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

Authors:  M Tohen; T G Jacobs; S L Grundy; S L McElroy; M C Banov; P G Janicak; T Sanger; R Risser; F Zhang; V Toma; J Francis; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-09

8.  A novel action of lithium: stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl D-aspartate receptor in monkey and mouse cerebral cortex slices.

Authors:  L E Hokin; J F Dixon; G V Los
Journal:  Adv Enzyme Regul       Date:  1996

9.  Glial reduction in the subgenual prefrontal cortex in mood disorders.

Authors:  D Ongür; W C Drevets; J L Price
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

Review 10.  Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders.

Authors:  W C Drevets; D Ongür; J L Price
Journal:  Mol Psychiatry       Date:  1998-05       Impact factor: 15.992

View more
  15 in total

1.  Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder.

Authors:  Rodrigo Machado-Vieira; Marcus V Zanetti; Antonio L Teixeira; Miyuki Uno; Leandro L Valiengo; Marcio G Soeiro-de-Souza; Sueli M Oba-Shinjo; Rafael T de Sousa; Carlos A Zarate; Wagner F Gattaz; Suely K N Marie
Journal:  Eur Neuropsychopharmacol       Date:  2015-02-16       Impact factor: 4.600

2.  Bcl-2 Overexpression Induces Neurite Outgrowth via the Bmp4/Tbx3/NeuroD1 Cascade in H19-7 Cells.

Authors:  Yun Young Lee; Hye-Jin Choi; So Young Lee; Shin-Young Park; Min-Jeong Kang; Jinil Han; Joong-Soo Han
Journal:  Cell Mol Neurobiol       Date:  2019-09-06       Impact factor: 5.046

3.  Investigation of Heschl's gyrus and planum temporale in patients with schizophrenia and bipolar disorder: a proton magnetic resonance spectroscopy study.

Authors:  M I Atagün; E M Şıkoğlu; S S Can; G Karakaş-Uğurlu; S Ulusoy-Kaymak; A Çayköylü; O Algın; M L Phillips; C M Moore; D Öngür
Journal:  Schizophr Res       Date:  2014-12-03       Impact factor: 4.939

Review 4.  Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  CNS Spectr       Date:  2013-03-11       Impact factor: 3.790

Review 5.  Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder.

Authors:  Rafael T de Sousa; Rodrigo Machado-Vieira; Carlos A Zarate; Husseini K Manji
Journal:  Expert Opin Ther Targets       Date:  2014-07-24       Impact factor: 6.902

6.  Bipolar disorder with comorbid binge eating history: a genome-wide association study implicates APOB.

Authors:  Stacey J Winham; Alfredo B Cuellar-Barboza; Susan L McElroy; Alfredo Oliveros; Scott Crow; Colin L Colby; Doo-Sup Choi; Mohit Chauhan; Mark A Frye; Joanna M Biernacka
Journal:  J Affect Disord       Date:  2014-04-19       Impact factor: 4.839

7.  Lithium-induced neuroprotection is associated with epigenetic modification of specific BDNF gene promoter and altered expression of apoptotic-regulatory proteins.

Authors:  Tushar Dwivedi; Hui Zhang
Journal:  Front Neurosci       Date:  2015-01-14       Impact factor: 4.677

8.  Dorsal Anterior Cingulate Lactate and Glutathione Levels in Euthymic Bipolar I Disorder: 1H-MRS Study.

Authors:  Márcio Gerhardt Soeiro-de-Souza; Bruno F Pastorello; Cláudia da Costa Leite; Anke Henning; Ricardo A Moreno; Maria Concepción Garcia Otaduy
Journal:  Int J Neuropsychopharmacol       Date:  2016-08-12       Impact factor: 5.176

9.  Unique prefrontal GABA and glutamate disturbances in co-occurring bipolar disorder and alcohol dependence.

Authors:  J J Prisciandaro; B K Tolliver; A P Prescot; H M Brenner; P F Renshaw; T R Brown; R F Anton
Journal:  Transl Psychiatry       Date:  2017-07-04       Impact factor: 6.222

10.  Bipolar disorder, a precursor of Parkinson's disease?

Authors:  Tânia M S Novaretti; Nathália Novaretti; Vitor Tumas
Journal:  Dement Neuropsychol       Date:  2016 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.